Could a common immune treatment save lives during sudden lung scarring attacks?
NCT ID NCT07299695
First seen Jan 04, 2026 · Last updated May 11, 2026 · Updated 15 times
Summary
This study tests whether adding intravenous immunoglobulin (IVIG) to standard care helps people hospitalized with sudden, severe worsening of idiopathic pulmonary fibrosis (IPF). About 196 adults with IPF and an acute flare-up will receive either usual treatment alone or usual treatment plus IVIG. The main goal is to see if IVIG reduces the chance of death or needing a breathing tube during the hospital stay.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Respiratory Medicine, University Hospital of Patras
RECRUITINGPátrai, 26504, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.